DCGO / DocGo Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

DocGo Announces Second Quarter 2025 Results Company Reiterates 2025 Revenue and Adjusted EBITDA Guidance, Increases Total Cash Balance to $128.7 Million, Signs New Contracts Across All Business Verticals Management to Host Conference Call and Webcast

Exhibit 99.1 DocGo Announces Second Quarter 2025 Results Company Reiterates 2025 Revenue and Adjusted EBITDA Guidance, Increases Total Cash Balance to $128.7 Million, Signs New Contracts Across All Business Verticals Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, August 7th, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 DOCGO INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

Non-GAAP Financial Information

Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor

Amended and Restated Credit Agreement, dated August 7, 2025, among DocGo Inc., the lender parties thereto, and Citibank, N.A., as administrative agent.

Exhibit 10.1 Execution Version AMENDED AND RESTATED CREDIT AGREEMENT Dated as of August 7, 2025 among DOCGO INC., as the Borrower, THE SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, CITIBANK, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and THE LENDERS PARTY HERETO ************************************************ CITIBANK, N.A., as Sole Lead Arranger and Sole Book

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 12, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Non-GAAP Financial Information

Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor

DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00

Exhibit 99.1 DocGo Announces First Quarter 2025 Results Company Focuses on Growing Medical Transportation and Payer & Provider Businesses, Navigates Municipal Uncertainty and Migrant Services Transition Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 8th, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-ena

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) DocGo Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 pe

As filed with the Securities and Exchange Commission on February 28, 2025

As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.

DocGo Announces Fourth Quarter and Full-Year 2024 Results Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host Conference Call and Webcast Tod

Exhibit 99.1 DocGo Announces Fourth Quarter and Full-Year 2024 Results Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, February 27, 2025 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of

Subsidiaries of DocGo Inc.

Exhibit 21.1 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2024 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United States Ambulnz Community Partners Ltd England and Wales

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396

Non-GAAP Financial Information

Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor

nsider Trading Policy.

Exhibit 19.1 INSIDER TRADING POLICY (dated April 24, 2023) I. INTRODUCTION DocGo Inc. (the “Company” or “DocGo”) is listed on the Nasdaq Stock Market (the “Nasdaq”), and is subject to its rules, as well as the rules and regulations of the Securities and Exchange Commission (“SEC”). U.S. Federal and state laws prohibit buying, selling, gifting or making other transfers of securities by persons who

tice and Agreement under the DocGo Inc. 2021 Stock Incentive Plan.

Exhibit 10.21 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the target number of performance stock units (“PSUs”) specified below (the “Award”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi

Joint Filing Agreement

EX-99.A 2 e664190ex99-a.htm Exhibit A Joint Filing Agreement The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of DocGo Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management

Exhibit B

EX-99.B 3 e664190ex99-b.htm Exhibit B Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 20, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi

DCGO / DocGo Inc. / VASHOVSKY STANLEY - SC 13D/A Activist Investment

SC 13D/A 1 schedule13da-svashovsky.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 DOCGO INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086 109 (CUSIP Number) 35 West 35th Street, Floor 6 New York, New York 10001 (844) 443-6246 (Name, Add

DCGO / DocGo Inc. / Flynn James E Passive Investment

SC 13G/A 1 e664029sc13ga-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * DocGo Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) September 30, 2024 (Dat

Non-GAAP Financial Information

Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

DocGo Announces Third Quarter 2024 Results Company Significantly Expands Operations on the West Coast to Support New Payer Programs, Increases Full-Year Guidance for Cash Flow from Operations Management to Host Conference Call and Webcast Today at 5:

Exhibit 99.1 DocGo Announces Third Quarter 2024 Results Company Significantly Expands Operations on the West Coast to Support New Payer Programs, Increases Full-Year Guidance for Cash Flow from Operations Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, November 7, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technolog

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 25, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Comm

DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board

Exhibit 99.1 DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board NEW YORK, September 30, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced the appointment of Stephen K. Klasko, M.D., M.B.A as the new independent, non-executive Chair of its Board of Directors, effective October 1,

Amended and Restated Form of Indemnification Agreement, by and between the Company and its officers and directors

Exhibit 10.1 AMENDED AND RESTATED INDEMNIFICATION AGREEMENT This Amended and Restated Indemnification Agreement (this “Agreement”) is entered into as of the date last signed below (the “Effective Date”) by and between DocGo Inc., a Delaware corporation (the “Company”), and the undersigned (the “Indemnitee”). RECITALS WHEREAS, the Board of Directors has determined that the inability to attract and

Consulting Agreement, dated September 27, 2024, by and between the Company and Steven Katz

Exhibit 10.2 TRANSITION CONSULTING AGREEMENT This TRANSITION CONSULTING AGREEMENT (this “Agreement”) is entered into by and between DocGo Inc., a Delaware corporation (the “Company”), and Steven Katz (“Consultant”). Consultant and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Consultant has resigned as a member of the Board of Directors (the “Boar

Second Amendment to Credit Agreement, dated May 7, 2024, by and

Exhibit 10.2 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of May 7, 2024 (this “Amendment”), is by and among DOCGO INC., a Delaware corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and CITIBANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”), Swingline Lender and L/C Issuer. Capitalized ter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

DocGo Announces Strong Second Quarter 2024 Results Company Raises Cash Flow From Operations Guidance to $80-$90 Million, Reiterates 2024 Revenue Guidance of $600-$650 Million and Adjusted EBITDA1 Guidance of $65-$75 Million Management to Host Confere

Exhibit 99.1 DocGo Announces Strong Second Quarter 2024 Results Company Raises Cash Flow From Operations Guidance to $80-$90 Million, Reiterates 2024 Revenue Guidance of $600-$650 Million and Adjusted EBITDA1 Guidance of $65-$75 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time (Note Corrected Call Information Below) NEW YORK, NY, August 7, 2024 – DocGo Inc. (Nas

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissi

Non-GAAP Financial Information

Exhibit 99.2 Non-GAAP Financial Information The following information provides the definition of adjusted gross margin as presented by DocGo Inc. (the “Company”), which is a financial measure that is not calculated or presented in accordance with generally accepted accounting principles (“GAAP”), and reconciliation to the most directly comparable financial measure calculated and presented in accor

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio

DocGo Inc. 35 West 35th Street, Floor 6 New York, New York 10001

DocGo Inc. 35 West 35th Street, Floor 6 New York, New York 10001 May 24, 2024 VIA EDGAR Christie Wong Michael Fay U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: DocGo Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 28, 2024 Form 8-K dated February 28, 2024

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission

DocGo Announces Strong First Quarter 2024 Results Company Reports First Quarter Net Income of $10.6 Million and Record Adjusted EBITDA1 of $24.1 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

Exhibit 99.1 DocGo Announces Strong First Quarter 2024 Results Company Reports First Quarter Net Income of $10.6 Million and Record Adjusted EBITDA1 of $24.1 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, May 8, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today anno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0

Amended and Restated Engagement Letter, dated April 18, 2024, by and between the Company and Ely D. Tendler Strategic and Legal Services, PLLC

Exhibit 10.3 Ely D. Tendler Strategic & Legal Services, PLLC Guidance through Experience April 18, 2024 CONFIDENTIAL Lee Bienstock, CEO Norm Rosenberg, CFO DocGo Inc. 35 West 35th Street New York, New York 10001 Re: Amended and Restated Engagement Letter Dear Lee and Norm, It has been our pleasure to work with Ambulnz, Inc. and DocGo Inc. (“DocGo”) these past eight-and-a-half years, and we look fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2024 DOCGO INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 8, 2024 DOCGO INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 8, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2024 DOCGO INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 7, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commissio

, by and between the Company and Stan Vashovsky.

Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between DocGo Inc., a Delaware corporation (the “Company”), and Stan Vashovsky (“Consultant”). Consultant and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, C

DCGO / DocGo Inc. / Hood River Capital Management LLC - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

ated August 3, 2023, by and between the Company and Stephen Sugrue.

Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of August 3, 2023 (the “Effective Date”), by and between Stephen Sugrue (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). WHEREAS, Executive has been serving as the Chief Compliance Officer of DocGo Inc. pursuant to that certain promotion letter, effective Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 DOCGO INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commi

(incorporated by reference to Exhibit 97.1 of the Company

Exhibit 97.1 DOCGO INC. COMPENSATION RECOUPMENT (CLAWBACK) POLICY (Effective November 15, 2023) Recoupment of Incentive-Based Compensation It is the policy of DocGo Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securi

Form of Performance Stock Unit Grant Notice and Agreement under the DocGo Inc. 2021 Stock Incentive Plan

Exhibit 10.17 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR PERFORMANCE STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the target number of performance stock units (“PSUs”) specified below (the “Award”) as performance-based Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each

Subsidiaries of DocGo Inc.

Exhibit 21.1 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2023 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United States Ambulnz Community Partners Ltd England and Wales

DocGo Announces Record Fourth Quarter and Full-Year 2023 Results Company Updates 2024 Revenue Guidance to $720-$750 Million, Introduces 2024 Adjusted EBITDA Guidance1 of $80-$85 Million Management to Host Conference Call and Webcast Today at 5:00 PM

DocGo Announces Record Fourth Quarter and Full-Year 2023 Results Company Updates 2024 Revenue Guidance to $720-$750 Million, Introduces 2024 Adjusted EBITDA Guidance1 of $80-$85 Million Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK, NY, February 28, 2024 – DocGo Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396

Description of Securities

Exhibit 4.2 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of the securities of DocGo Inc. (“DocGo”) registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including certain provisions of the Delaware General Corporation Law (as the same exists or may hereafter be amended, the “DGCL”), the Second Amended and Re

DCGO / DocGo Inc. / Hood River Capital Management LLC - AMENDMENT NO. 1 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

DCGO / DocGo Inc. / Flynn James E Passive Investment

SC 13G/A 1 e619243sc13ga-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * DocGo Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2023 (Date

.A., as administrative agent (incorporated by reference to Exhibit 10.1

Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of January 30, 2024 (this “Amendment”), is by and among DOCGO INC., a Delaware corporation (the “Borrower”) and CITIBANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”), Swingline Lender and L/C Issuer. Capitalized terms used herein and not otherwise defined herein shal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2024 DOCGO INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 30, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

DocGo Announces Share Buyback Program

Exhibit 99.1 DocGo Announces Share Buyback Program NEW YORK, NY, January 31, 2024 – DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that its Board of Directors has approved a new share repurchase program pursuant to which DocGo may purchase up to $36 million of its common stock during a 6-month period ending Jul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 16, 2024 DOCGO INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 16, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

DocGo Provides Additional Information to Refute Misleading Short Seller “Report”

DocGo Provides Additional Information to Refute Misleading Short Seller “Report” NEW YORK – (Business Wire) – January 16, 2024 – As previously disclosed in our press release dated January 10, 2024, DocGo Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2024 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance

DocGo Rejects Short Seller Report and Releases Preliminary 2024 Revenue Guidance NEW YORK – (Business Wire) – January 10, 2024 – DocGo Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

, 2023, by and between the Company and Lee Bienstock.

Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 2, 2023 (the “Effective Date”), by and between Lee Bienstock (“Executive”) and DocGo Inc., a Delaware corporation (the “Company”). WHEREAS, Executive was serving as the President and Chief Operating Officer of the Company pursuant to that certain offer letter, effective

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2023).

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DOCGO INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of DocGo Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”). Section 1.2 Other Offices. The Corpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

DocGo Announces Record Third Quarter 2023 Results Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And Increases Adjusted EBITDA1 Guidance to $50-$55 Million, up From a Previous Range of $48-$53

Exhibit 99.1 DocGo Announces Record Third Quarter 2023 Results Company Raises 2023 Revenue Guidance to $615-$625 Million, up From a Previous Range of $540-$550 Million And Increases Adjusted EBITDA1 Guidance to $50-$55 Million, up From a Previous Range of $48-$53 Million Management to Host Conference Call and Webcast Today at 5:00 p.m. EDT NEW YORK, NY, November 6, 2023 – DocGo Inc. (Nasdaq: DCGO)

October 10, 2023

Exhibit 99.1 KATHY HOCHUL Governor BARBARA C. GUINN Acting Commissioner October 10, 2023 Mr. George Sarkissian Chief of Staff NYC Housing and Development 100 Gold Street New York, NY 10038 Dear Mr. Sarkissian: The New York State Office of Temporary and Disability Assistance (OTDA) has completed a review of the provisions of services to individuals placed by New York City in temporary housing in ho

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 10, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

DCGO / DocGo Inc / Flynn James E Passive Investment

SC 13G 1 e619014sc13g-docgo.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * DocGo inc. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) October 9, 2023 (Date of Ev

Separation and Transition Services Agreement, dated October 11, 2023, by and between the Company and Anthony Capone (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 13, 2023).

Exhibit 10.1 SEPARATION AND TRANSITION SERVICES AGREEMENT This SEPARATION AND TRANSITION SERVICES AGREEMENT (this “Agreement”) is entered into on this 11th day of October, 2023 by and between DocGo, Inc. (the “Company”) and Anthony Capone (“Executive”). Executive and the Company are each referred to herein as a “Party” and collectively as the “Parties.” WHEREAS, Executive resigned his employment w

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 11, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation or organization) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numb

ADOLFO CARRIÓN JR.

Exhibit 99.1 ADOLFO CARRIÓN JR. Commissioner Office of the Commissioner 100 Gold Street New York, N.Y. 10038 September 6, 2023 Anthony Capone Chief Executive Officer Rapid Reliable Testing NY, LLC (d/b/a DocGo) 35 West 35th Street New York, New York 10001 Re: Rapid Reliable Testing NY LLC Contract #20248801671 Dear Mr. Capone, I refer to the letter received by my office yesterday from New York Cit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 DOCGO INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ¨

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:

Form of Grant Notice for Restricted Stock Unit Award and Standard Terms and Conditions for Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (Employee Form)

DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”) hereby grants to the Participant named below the number of Restricted Stock Units (the “RSUs”) specified below (the “Award”) under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each RSU represents the right to receive one share of Common Stock,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ¨ TRANSITION REPORT PU

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 DOCGO INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

DocGo Announces Record Second Quarter 2023 Results Company Raises 2023 Revenue Guidance To $540-$550 Million Increases Adjusted EBITDA1 Guidance To $48-$53 Million

Exhibit 99.1 DocGo Announces Record Second Quarter 2023 Results Company Raises 2023 Revenue Guidance To $540-$550 Million Increases Adjusted EBITDA1 Guidance To $48-$53 Million NEW YORK, NY, August 7, 2023 – DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced financial and operating results for the quarter ended June 30, 2023. Q2 2023 Financial Highlig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (

1 01 02 03 04 Proactive Health Care Revolution 05 06 07 08 Excellence In Operations Care Delivery Growth Trajectory Clinical Excellence Q&A Technology Executing Our Vision AGENDA Cautionary Note Regarding Forward - Looking Statements This presentatio

Exhibit 99.1 1 01 02 03 04 Proactive Health Care Revolution 05 06 07 08 Excellence In Operations Care Delivery Growth Trajectory Clinical Excellence Q&A Technology Executing Our Vision AGENDA Cautionary Note Regarding Forward - Looking Statements This presentation includes forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (

Offer Letter by and between DocGo Inc. and Lee Bienstock.

Exhibit 10.1 35 West 35th Street 6th FL New York, NY 10001 Lee Bienstock Dear Lee, Congratulations! We are pleased to offer you the position of Chief Operating Officer for DocGo, Inc. We're just a few formalities away from getting down to work. Please take the time to review our formal offer. It includes important details about your compensation, benefits and the terms and conditions of your antic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-39618 DocGo In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 DOCGO INC. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (IR

DocGo Announces First Quarter 2023 Results Company Reiterates 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA1 Guidance of $45-$50 million

Exhibit 99.1 DocGo Announces First Quarter 2023 Results Company Reiterates 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA1 Guidance of $45-$50 million NEW YORK, NY, May 8th, 2023 – DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced financial and operating results for the quarter ended March 31, 2023. Q1 2023 Financial Highlights ● Tota

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission file num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Num

Form of Grant Notice for Restricted Stock Unit Award and Standard Terms and Conditions for Restricted Stock Units under the DocGo Inc. 2021 Stock Incentive Plan (Director Form)

Exhibit 10.10 DIRECTOR FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR RESTRICTED STOCK UNIT AWARD FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ”Company”) hereby grants to the Participant named below the number of Restricted Stock Units (the “RSUs”) specified below (the “Award”) under the DocGo Inc. 2021 Stock Incentive Plan (the “Plan”). Each RSU represents the right to receive

Form of Grant Notice for Incentive Stock Options and Standard Terms and Conditions for Incentive Stock Options under the DocGo Inc. 2021 Stock Incentive Plan

Exhibit 10.12 EMPLOYEE FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR INCENTIVE STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo, Inc. (the “Company”), hereby grants to Participant named below the Incentive Stock Option (the “Option”) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39618 DocGo Inc. (Exa

Form of Grant Notice for Nonqualified Stock Options and Standard Terms and Conditions for Nonqualified Stock Options under the DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K filed with the SEC on March 14, 2023).

Exhibit 10.11 EMPLOYEE FORM DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the “Company”), hereby grants to Participant named below the Nonqualified Stock Option (the “Option”) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each sp

Subsidiaries of DocGo Inc.

Exhibit 21 Subsidiaries of DocGo Inc. The registrant’s subsidiaries and affiliates as of December 31, 2022 are included in the list below. Name Jurisdiction AF DE LNZ LLC Delaware, United States AF PR Ambulnz, LLC Puerto Rico, United States Territory AF WI LNZ, LLC Wisconsin, United States AF WI, LLC Wisconsin, United States Ambulnz AL, LLC Alabama, United States Ambulnz CO, LLC Colorado, United S

Description of Securities

Exhibit 4.2 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of DocGo Inc.’s (“DocGo”) securities, including certain provisions of the Delaware General Corporation Law (as the same exists or may hereafter be amended (the “DGCL”)), the Second Amended and Restated Certificate of Incorporation of DocGo (the “Charter”) and the Amended and Restated Bylaws of DocGo (the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DOCGO INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

DocGo Announces Fourth Quarter and Full-Year 2022 Results 2022 Revenue Increased to $440.5 Million, Versus $318.7 Million in 2021, an Increase of 38% Full Year Revenue up 75% Year-Over-Year Excluding Mass Covid Testing Company introduces Full-Year 20

Exhibit 99.1 DocGo Announces Fourth Quarter and Full-Year 2022 Results 2022 Revenue Increased to $440.5 Million, Versus $318.7 Million in 2021, an Increase of 38% Full Year Revenue up 75% Year-Over-Year Excluding Mass Covid Testing Company introduces Full-Year 2023 Revenue and Adjusted EBITDA1 Guidance of $500-$510 million and $45-$50 million, respectively Company to host investor conference call

DocGo Awarded $180M in New Business in the United States, United Kingdom Since January as Demand for Mobile Healthcare Grows Volume of new business demonstrates strong growth across key mobile health, medical transportation service lines

Exhibit 99.2 DocGo Awarded $180M in New Business in the United States, United Kingdom Since January as Demand for Mobile Healthcare Grows Volume of new business demonstrates strong growth across key mobile health, medical transportation service lines March 13, 2023 - (New York, NY) DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services, announced today that since the start of

DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP - SC 13G/A Passive Investment

SC 13G/A 1 d460148dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro

JOINT FILING AGREEMENT

EX-99.A 2 d460148dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Amendment No. 2 to Schedule 13G with respect to the Common stock, par value $0.0001 per share of DocGo Inc., dated as of February 14, 2023, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of

POWER OF ATTORNEY

EX-99.B 3 d460148dex99b.htm EX-99.B EXHIBIT B POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENT, that I, Louis M. Bacon, hereby make constitute and appoint each of James E. Kaye and James Danza, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name (a) in my personal capacity or (b) in my capacity as Chairman and Chief Executive Officer of each of Moore Capita

DCGO / DocGo Inc / Hood River Capital Management LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DOCGO INC. (Name of Issuer) Common Stock (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f

Up to 17,778,588 Shares of Common Stock

Prospectus Supplement No. 1 (to prospectus dated December 29, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 17,778,588 Shares of Common Stock This prospectus supplement no. 1 is being filed to update and supplement the prospectus dated December 29, 2022 (the “Prospectus”) related to the offer and sale, from time to time, by the Selling Securityholders (as defined in the

Up to 17,778,588 Shares of Common Stock

424B3 1 ea171102-424b3docgo.htm PROSPECTUS PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 17,778,588 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of up to 17,778,588 shares of our Common Stock. We will not receive any proceeds from the sale of shares of Common Stock by t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2022 DOCGO INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe

DocGo Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors

Exhibit 99.1 DocGo Announces Stan Vashovsky to Continue to Serve as Chairman of its Board of Directors NEW YORK (December 29, 2022) ? (Business Wire) ? DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that its co-founder and current Chairman of the Board and Chief Executive Officer Stan Vashovsky will continue to serve as non-executive Chairman of

As filed with the Securities and Exchange Commission on December 23, 2022

As filed with the Securities and Exchange Commission on December 23, 2022 Registration No.

Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) DocGo Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe

DocGo Appoints Veteran Technology Human Resources Executive Vina Leite, MS, to its Board of Directors and Announces Key Leadership Promotions

Exhibit 99.1 DocGo Appoints Veteran Technology Human Resources Executive Vina Leite, MS, to its Board of Directors and Announces Key Leadership Promotions NEW YORK (Nov. 14, 2022) – (Business Wire) – DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced that it has appointed veteran human resources executive Vina Leite, MS, to its Board of Directors. Ms. Lei

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 11 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 11 is being filed to update and supplement the prospectus dated March 22, 2022 (the “Prospe

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 13 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 13 is being filed to update and supplement the prospectus dated March 22, 2022 (the “Prospe

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

424B3 1 ea168325-424b3docgo.htm PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 12 is being filed to update an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39618 DocGo

DocGo Announces Strong Third Quarter 2022 Results Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his retirement effective December 31s

Exhibit 99.1 DocGo Announces Strong Third Quarter 2022 Results Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his retirement effective December 31st; DocGo President Anthony Capone named new CEO; Mr. Vashovsky will consult with the Company through 2023 to assist with the transition C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 DOCGO INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number

Credit Agreement, dated November 1, 2022, among DocGo Inc., the lender parties thereto, and Citibank, N.A., as administrative agent.

Exhibit 10.1 Execution Copy CREDIT AGREEMENT Dated as of November 1, 2022 among DOCGO INC., as the Borrower, THE SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, CITIBANK, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, BANK OF THE WEST, as Documentation Agent, and THE LENDERS PARTY HERETO ************************************************ CITIBANK, N.A., as Sole Lead Ar

DocGo Announces $90 Million Line of Credit with Citibank, N.A. Available funds to be used for opportunistic M&A and working capital as needed

Exhibit 99.1 DocGo Announces $90 Million Line of Credit with Citibank, N.A. Available funds to be used for opportunistic M&A and working capital as needed NEW YORK (Nov. 2, 2022) ? (Business Wire) ? DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced that it has entered into a $90 million secured line of credit (LOC) with Citibank, N.A. as the Administrati

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 10 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 10 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospe

NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 256086117)

Exhibit 99.2 August 15, 2022 NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 256086117) Dear Warrant Holder, DocGo Inc. (the ?Company?) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on September 16, 2022 (the ?Redemption Date?), all of the Company?s outstanding Warrants (as defined in the Warrant Agreement (defined below)) (the ?Warrants?) to purchase shares of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 9 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 9 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

DocGo Announces Redemption of All Outstanding Warrants

Exhibit 99.1 FOR IMMEDIATE RELEASE? DocGo Announces Redemption of All Outstanding Warrants NEW YORK ? August 15, 2022 ? DocGo Inc. , a leading provider of last-mile mobile health services and integrated ambulance medical transportation solutions (Nasdaq: DCGO), announced today that it will redeem all of its outstanding warrants (the ?Public Warrants?) to purchase shares of DocGo?s common stock, pa

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 8 Filed Pursuant to Rule 424(b)(3) (to prospectus dated March 22, 2022) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 8 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 7 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 7 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39618 DocGo In

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 6 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 6 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

DocGo Announces Strong Second Quarter 2022 Results Q2 Revenue of $109.5 Million Up 76% Year-Over-Year; Company Raises Full-Year 2022 Guidance

Exhibit 99.1 DocGo Announces Strong Second Quarter 2022 Results Q2 Revenue of $109.5 Million Up 76% Year-Over-Year; Company Raises Full-Year 2022 Guidance NEW YORK, NY, August 8, 2022 - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced financial and operating results for the second quarter ending June 30, 2022. Second Quarter Financial Highlights ?

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 5 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 5 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 4 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 4 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (I

DocGo Announces Share Repurchase Program of Up To $40 Million

Exhibit 99.1 DocGo Announces Share Repurchase Program of Up To $40 Million May 24, 2022 ? (New York, NY) ? DocGo (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical transportation solutions, announced today that its Board of Directors has authorized a share repurchase program pursuant to which the Company may purchase up to $40 million of its Common Stock.

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 3 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 3 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

DocGo Inc. 2021 Stock Incentive Plan

Exhibit 10.4 DOCGO, INC. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this DocGo, Inc. 2021 Stock Incentive Plan (the ?Plan?) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of DocGo, Inc. (the ?Company?) and its stockholders by providing stock-based compensation. The objectives of the Plan are to attract and retain th

Form of Restricted Stock Unit Grant Notice and Agreement

Exhibit 10.3 RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT DocGo Inc. (the ?Company?), pursuant to its 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time, the ?Plan?), hereby grants to Holder the number of the number of Restricted Stock Units set forth below, each Restricted Stock Unit being a notional unit representing the right to receive one share

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number) (IR

Form of Grant Notice for Incentive Stock Options

Exhibit 10.2 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR INCENTIVE STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ?Company?), hereby grants to Participant named below the Incentive Stock Option (the ?Option?) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below, and up

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-39618 DocGo In

Form of Grant Notice for Nonqualified Stock Options

Exhibit 10.1 DOCGO INC. 2021 STOCK INCENTIVE PLAN GRANT NOTICE FOR NONQUALIFIED STOCK OPTIONS FOR GOOD AND VALUABLE CONSIDERATION, DocGo Inc. (the ?Company?), hereby grants to Participant named below the Nonqualified Stock Option (the ?Option?) to purchase any part or all of the number of shares of Common Stock that are covered by this Option at the Exercise Price per share, each specified below,

DocGo Announces Strong First Quarter 2022 Results Q1 Revenue of $118 Million Up 137% Over Comparable Prior Year Period Bolsters Senior Staff, Expands Market Footprint

Exhibit 99.1 DocGo Announces Strong First Quarter 2022 Results Q1 Revenue of $118 Million Up 137% Over Comparable Prior Year Period Bolsters Senior Staff, Expands Market Footprint NEW YORK, NY, May 9, 2022 - DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services and integrated medical transportation solutions, today announced financial and operating results for the first quart

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ??? ? ? Preliminary Proxy Statement ??? ? ? Confidential, for Use of the Commission Only (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 2 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 2 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 1 (to prospectus dated March 22, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 1 is being filed to update and supplement the prospectus dated March 22, 2022 (the ?Prospect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3

Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 PROSPECTUS Up to 22,223,858 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of: (i) up to 22,223,858 shares of our Common Stock and (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Comm

DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services

Exhibit 99.1 FOR IMMEDIATE RELEASE DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services NEW YORK, March 14, 2022?DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced

As filed with the Securities and Exchange Commission on March 15, 2022

As filed with the Securities and Exchange Commission on March 15, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39618 DocGo Inc. (Exa

Description of Securities (incorporated by reference to Exhibit 4.3 of DocGo’s Form 10-K, filed with the SEC on March 15, 2022).

Exhibit 4.3 DESCRIPTION OF SECURITIES The following sets forth a summary of the material terms of our securities, including certain provisions of Delaware law and of the Second Amended and Restated Certificate of Incorporation (the ?Charter?) of DocGo Inc. (?DocGo?), the Amended and Restated Bylaws of DocGo (the ?Bylaws?) and the Warrant Agreement, dated October 14, 2020, by and between DocGo (fka

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services

Exhibit 99.1 FOR IMMEDIATE RELEASE DocGo Names Lee Bienstock as Chief Operating Officer to Drive Strategic Expansion Bienstock joins DocGo from Google, where he most recently served as Global Head of Enterprise Partnerships, Devices and Services NEW YORK, March 14, 2022?DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced

DocGo Announces Record Fourth Quarter and Full Year 2021 Results Q4 and full year revenue increased 289% and 239%, respectively, over comparable prior year periods Positive adjusted EBITDA and net income for both the quarter and full year

Exhibit 99.1 DocGo Announces Record Fourth Quarter and Full Year 2021 Results Q4 and full year revenue increased 289% and 239%, respectively, over comparable prior year periods Positive adjusted EBITDA and net income for both the quarter and full year NEW YORK, NY, March 14, 2022 - DocGo (Nasdaq:DCGO), a leading provider of last-mile mobile health services and integrated medical transportation sol

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number)

DCGO / DocGo Inc / Radcliffe Capital Management, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* DocGo Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 20

DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

DCGO / DocGo Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - DOCGO INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (formerly known as Motion Acquisition Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate

DCGO / DocGo Inc / Weiss Asset Management LP Passive Investment

CUSIP NO. 256086109 SCHEDULE 13G/A PAGE 1 OF 10 PAGES =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DOCGO INC. (FORMERLY KNOWN AS MOTION ACQUISITION CORP) - (Name of Issuer) Common Stock, par value $0.0001 per share -

Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Prospectus Supplement No. 1 (to prospectus dated January 3, 2022) Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus supplement no. 1 is being filed to update and supplement information contained in the prospectus dated Jan

DCGO / DocGo Inc / Linden Capital L.P. - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru

DocGo Announces Record Preliminary Fourth Quarter 2021 Revenue Full year and fourth quarter revenue of $305.0 million and $107.8 million, respectively, more than triple versus prior year periods

Exhibit 99.1 DocGo Announces Record Preliminary Fourth Quarter 2021 Revenue Full year and fourth quarter revenue of $305.0 million and $107.8 million, respectively, more than triple versus prior year periods January 28, 2022 - (New York, NY) ?DocGo, (Nasdaq: DCGO), a leading provider of last-mile mobile health services and integrated medical mobility solutions, announced today select preliminary u

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction (Commission (IRS Employer of incorporatio

As filed with the Securities and Exchange Commission on January 11, 2022

As filed with the Securities and Exchange Commission on January 11, 2022 Registration No.

Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261363 PROSPECTUS Up to 28,234,175 Shares of Common Stock Up to 6,317,057 Shares of Common Stock Issuable Upon Exercise of the Warrants Up to 2,533,333 Private Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus of: (i) up to 28,234,175 shares of our Common Stock and (

December 29, 2021

December 29, 2021 VIA EDGAR Anuja Majmudar Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, NE Washington, D.

As filed with the Securities and Exchange Commission on December 15, 2021

As filed with the Securities and Exchange Commission on December 15, 2021 Registration No.

* * *

CORRESP 1 filename1.htm Evan M. D’Amico Direct: +1 202.887.3613 Fax: +1 202.530.4255 [email protected] December 15, 2021 VIA EDGAR Anuja Majmudar Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, NE Washington, D.C. 20549-3561 Re: DocGo Inc. Registration Statement on Form S-1 Filed November 24, 2021 File No. 333-261363 Dear Ms.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number

DocGo Announces Increase in Full-Year 2021 Guidance Annual revenues expected to reach over $290 million, Adjusted EBITDA of at least $12 million

Exhibit 99.1 DocGo Announces Increase in Full-Year 2021 Guidance Annual revenues expected to reach over $290 million, Adjusted EBITDA of at least $12 million December 1, 2021 - (New York, NY) ? DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions (Nasdaq:DCGO), announced today that it is updating and increasing its full-year 2021 guidance for both

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DOCGO INC. (Exact Name of Registrant as Specifie

As filed with the Securities and Exchange Commission on November 24, 2021

As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MOTION ACQUISITION CORP. (Exact Name of

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Numbe

Ambulnz, Inc. and Subsidiaries CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIODS ENDED SEPTEMBER 30, 2021 and 2020

Exhibit 99.1 Ambulnz, Inc. and Subsidiaries CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIODS ENDED SEPTEMBER 30, 2021 and 2020 Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months and Nine Months Ended September 30, 2021 and Septemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DOCGO INC. (Exact Name of Registrant as Specified

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K/A to which this Unaudited Pro Forma Condensed Combined Financial Information is attached (the ?Form 8-K/A?) and, if not defined in the Form 8-K/A, the proxy statement/consent solicitation/prospectus (th

DCGO / DocGo Inc / VASHOVSKY STANLEY - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Amendment No.)* UNDER THE SECURITIES EXCHANGE ACT OF 1934 DOCGO INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 256086 109 (CUSIP Number) 35 West 35th Street, Floor 5 New York, New York 10001 (888) 927-7296 (Name, Address and Telephone Number of Person Authorized to

DOCGO’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 DOCGO’S MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of DocGo’s financial condition and results of operations should be read in conjunction with its consolidated statements, the accompanying notes, and other financial information included elsewhere in this current report on Form 8-K filing. This discussion

DCGO / DocGo Inc / MOORE CAPITAL MANAGEMENT, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DocGo Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 256086109 (CUSIP Number) November 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 (November 5, 2021) DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (

Second Amended and Restated Certificate of Incorporation of DocGo Inc., dated November 5, 2021 (incorporated by reference to Exhibit 3.1 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MOTION ACQUISITION CORP. (a Delaware corporation) Motion Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is ?Motion Acquisition Corp.,? and is changing its name to ?DocGo Inc.? pursuant to this Secon

Form of Indemnification Agreement of DocGo Inc. (incorporated by reference to Exhibit 10.10 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 10.10 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is entered into as of November , 2021 (the ?Effective Date?) by and between DocGo Inc., a Delaware corporation (the ?Company?), and the undersigned (the ?Indemnitee?). RECITALS WHEREAS, the Board of Directors has determined that the inability to attract and retain qualified persons as directors and of

Amended and Restated Registration Rights Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC, and Stan Vashovsky (incorporated by reference to Exhibit 10.4 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 10.4 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into as of November 5, 2021, by and among Motion Acquisition Corp., a Delaware corporation (the ?Company?) and the undersigned parties listed under Investors on the signature page hereto (each, an ?Investor? and collectively, the ?Investors?). WHEREA

Letter from WithumSmith+Brown, PC addressed to the Securities and Exchange Commission, dated as of November 10, 2021 (incorporated by reference to Exhibit 16.1 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021)

EX-16.1 13 ea150082ex16-1docgoinc.htm LETTER FROM WITHUMSMITH+BROWN, PC ADDRESSED TO THE SECURITIES AND EXCHANGE COMMISSION, DATED AS OF NOVEMBER 5, 2021 Exhibit 16.1 November 10, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read Docgo Inc. (formerly known as Motion Acquisition Corp.) statements include

New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Anthony Capone (incorporated by reference to Exhibit 10.8 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Anthony Capone (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Technology Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?) pursu

DocGo Inc. Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

EX-14.1 12 ea150082ex14-1docgoinc.htm DOCGO INC. CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS (dated November 5, 2021) I. INTRODUCTION This Code of Business Conduct and Ethics (this “Code”) provides a general statement of the expectations of DocGo Inc. (the “Company” or “DocGo”) regarding the ethical standards to which each director, officer and employee sho

New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Andre Oberholzer (incorporated by reference to Exhibit 10.7 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Andre Oberholzer (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Financial Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?) purs

New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Stan Vashovsky (incorporated by reference to Exhibit 10.6 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of November 5, 2021, by and between Stan Vashovsky (?Executive?) and Motion Acquisition Corp., a Delaware corporation (the ?Company?). WHEREAS, Executive has been serving as the Chief Executive Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (?Ambulnz?); WHERE

Stock Escrow Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC, and Continental Stock & Transfer Company (incorporated by reference to Exhibit 10.11 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

EX-10.11 11 ea150082ex10-11docgoinc.htm STOCK ESCROW AGREEMENT, DATED AS OF NOVEMBER 5, 2021, BY AND AMONG MOTION ACQUISITION CORP., MOTION ACQUISITION LLC, AND CONTINENTAL STOCK & TRANSFER COMPANY Exhibit 10.11 STOCK ESCROW AGREEMENT STOCK ESCROW AGREEMENT, dated as of November 5, 2021 (“Agreement”), by and among Motion Acquisition Corp. (to be renamed DocGo Inc.), a Delaware corporation (“Parent

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial Information is attached (the ?Form 8-K?) and, if not defined in the Form 8-K, the proxy statement/consent solicitation prospectus filed wit

New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Norm Rosenberg (incorporated by reference to Exhibit 10.9 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

EX-10.9 9 ea150082ex10-9docgoinc.htm NEW EXECUTIVE AGREEMENT, EFFECTIVE NOVEMBER 5, 2021, BY AND BETWEEN MOTION ACQUISITION CORP. AND NORM ROSENBERG Exhibit 10.9 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of November 5, 2021, by and between Norman Rosenburg (“Executive”) and Motion Acquisition Corp., a Delaware corporation (the “Company”

Amended and Restated Bylaws of DocGo Inc. (incorporated by reference to Exhibit 3.2 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DOCGO INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of DocGo Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, excep

Specimen Common Stock Certificate of DocGo Inc. (incorporated by reference to Exhibit 4.3 of DocGo’s Form 8-K, filed with the SEC on November 12, 2021).

Exhibit 4.3 SPECIMEN COMMON STOCK CERTIFICATE NUMBER NUMBER OF SHARES OF COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 256086 109 DOCGO INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE OF $0.0001 PER SHARE, OF DOCGO INC. (THE ?COMPANY?) transferable on the books of the

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2021 DOCGO INC. (Exact name of registrant as specified in its charter) Delaware 001-39618 85-2515483 (State or other jurisdiction of incorporation) (Commission File Number

Amended and Restated Sponsor Agreement, dated as of November 4, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC and Ambulnz, Inc. (incorporated by reference to Exhibit 10.1 of Motion’s Form 8-K, filed with the SEC on November 5, 2021).

EX-10.1 2 ea149877ex10-1motionacq.htm A&R SPONSOR AGREEMENT, DATED NOVEMBER 4, 2021, BY AND AMONG MOTION ACQUISITION CORP., MOTION ACQUISITION LLC AND AMBULNZ, INC Exhibit 10.1 AMENDED AND RESTATED SPONSOR AGREEMENT This AMENDED AND RESTATED SPONSOR AGREEMENT (the “A&R Sponsor Agreement”), dated as of November 4, 2021, is entered into by and between Motion Acquisition LLC, a Delaware limited liabi

Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination

EX-99.1 3 ea149877ex99-1motionacq.htm PRESS RELEASE, DATED NOVEMBER 2, 2021 Exhibit 99.1 Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination November 2, 2021 - (New York, NY) – Motion Acquisition Corp. (“Motion”) (Nasdaq: MOTN), a special purpose acquisition company, and its merger partner Ambulnz, Inc., dba DocGo, a leading provider of Mobile Health services a

Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination

Exhibit 99.1 Motion Acquisition Corp. and DocGo Announce Shareholder Approval Of Business Combination November 2, 2021 - (New York, NY) ? Motion Acquisition Corp. (?Motion?) (Nasdaq: MOTN), a special purpose acquisition company, and its merger partner Ambulnz, Inc., dba DocGo, a leading provider of Mobile Health services and integrated medical mobility solutions, announced today that their previou

A&R Sponsor Agreement, dated November 4, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC and Ambulnz, Inc.

EX-10.1 2 ea149877ex10-1motionacq.htm A&R SPONSOR AGREEMENT, DATED NOVEMBER 4, 2021, BY AND AMONG MOTION ACQUISITION CORP., MOTION ACQUISITION LLC AND AMBULNZ, INC Exhibit 10.1 AMENDED AND RESTATED SPONSOR AGREEMENT This AMENDED AND RESTATED SPONSOR AGREEMENT (the “A&R Sponsor Agreement”), dated as of November 4, 2021, is entered into by and between Motion Acquisition LLC, a Delaware limited liabi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 MOTION ACQUISITI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 MOTION ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-39618 85-2515483 (State or Other Jurisdiction of Incorporation) (Commission F

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 MOTION ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-39618 85-2515483 (State or Other Jurisdiction of Incorporation) (Commission F

© 2021 All Rights Reserved – DocGo Investor Presentation February 2021 Investor Presentation October 2021 WHERE TELEHEALTH STOPS, WE GO © 2021 All Rights Reserved – DocGo Disclaimer This presentation contemplates a business combination pursuant to a

Filed by Motion Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Motion Acquisition Corp. Related Registration Statement File No. 333-257681 ? 2021 All Rights Reserved ? DocGo Investor Presentation February 2021 Investor Presentation October 2021 WHERE TELEHEALTH STOPS, WE GO

Motion Acquisition Corp. and DocGo Announce DocGo’s Record Preliminary Third Quarter 2021 Revenue Third quarter revenue expected to triple year-over-year to $81 million DocGo raises full-year revenue outlook to $260 million driven by positive busines

Filed by Motion Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Motion Acquisition Corp. Related Registration Statement File No. 333-257681 Motion Acquisition Corp. and DocGo Announce DocGo?s Record Preliminary Third Quarter 2021 Revenue Third quarter revenue expected to trip

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257681 PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS OF MOTION ACQUISITION CORP. PROSPECTUS FOR UP TO 88,600,000 SHARES OF CLASS A COMMON STOCK

Filed Pursuant to Rule 424(b)(3) Registration No. 333-257681 PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS OF MOTION ACQUISITION CORP. PROSPECTUS FOR UP TO 88,600,000 SHARES OF CLASS A COMMON STOCK On March 8, 2021, Motion Acquisition Corp., a Delaware corporation (?Motion?), entered into a Merger Agreement (the ?Merger Agreement?) with Motion Merger Sub Corp., a Delaware corporation and whol

Motion Acquisition Corp. Announces Effectiveness of Registration Statement and Date for Annual Meeting to Approve Proposed Business Combination with DocGo Meeting Scheduled for November 2, 2021 Stockholders of Record as of September 9, 2021 are Eligi

Filed by Motion Acquisition Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Motion Acquisition Corp. Related Registration Statement File No. 333-257681 Motion Acquisition Corp. Announces Effectiveness of Registration Statement and Date for Annual Meeting to Approve Proposed Business Comb

Motion Acquisition Corp. c/o Graubard Miller The Chrysler Building 405 Lexington Avenue New York, New York 10174 (212) 818-8800

Motion Acquisition Corp. c/o Graubard Miller The Chrysler Building 405 Lexington Avenue New York, New York 10174 (212) 818-8800 October 13, 2021 Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Motion Acquisition Corp. Registration Statement on Form S-4 File No. 333-257681 Ladies and Gentlemen: Pursuant to R

Form of Motion Acquisition Corp. Proxy Card.

EX-99.1 4 fs42021a5ex99-1motionacq.htm FORM OF MOTION ACQUISITION CORP. PROXY CARD Exhibit 99.1 PRELIMINARY PROXY MOTION ACQUISITION CORP. c/o Graubard Miller The Chrysler Building 405 Lexington Ave New York, NY 10174 (212) 818-8800 ANNUAL MEETING YOUR VOTE IS IMPORTANT THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL Meeting TO BE HELD ON NOVEMBER 2, 2021 The undersigned, revoking

DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No. 5 to the Company’s Registration Statement on Form S-4/A filed on October 7, 2021).

EX-10.8 2 fs42021a5ex10-8motionacq.htm FORM OF 2021 INCENTIVE PLAN Exhibit 10.8 Adopted by the Board of Directors of Motion Acquisition Corp. on March 4, 2021 DOCGO, INC. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this DocGo, Inc. 2021 Stock Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers

Subsidiaries of DocGo Inc. (incorporated by reference to Exhibit 21.1 to Motion’s Proxy Statement/Consent Solicitation/Prospectus (File No. 333-257681), filed with the SEC on October 7, 2021, as amended).

EX-21.1 3 fs42021a5ex21-1motionacq.htm LIST OF SUBSIDIARIES OF NEW DOCGO Exhibit 21.1 DocGo Inc. Subsidiaries Following the Consummation of the Business Combination 100% Owned Subsidiaries 50% Owned Subsidiaries 1. Ambulnz, Inc. 1. Ambulnz CO, LLC 2. Ambulnz Holdings, LLC 2. Ambulnz NJ-PA, LLC 3. Ambulnz AL, LLC 3. Ambulnz NJ, LLC 4. Ambulnz GA, LLC 4. Ambulnz PA, LLC 5. Ambulnz Health, LLC 5. Amb

Form of Ambulnz, Inc. Written Consent

Exhibit 99.2 ACTION BY WRITTEN CONSENT IN LIEU OF A MEETING OF THE STOCKHOLDERS OF AMBULNZ, INC. October [], 2021 The undersigned, being holders of Class A Common Stock (?Common Stockholders?) and Series A Preferred Stock (?Preferred Stockholders?) of Ambulnz, Inc., a Delaware corporation (the ?Company?), acting in accordance with Sections 228 and 251 of the General Corporation Law of Delaware (th

As filed with the Securities and Exchange Commission on October 7, 2021

As filed with the Securities and Exchange Commission on October 7, 2021 No. 333-257681 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOTION ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-2515483 (State or other jurisdiction of incorporation or organization) (Pr

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800 Facsimile direct dial number (212) 818-8881 (212) 818-8638 email address [email protected] October 1, 2021 Division of Corporation Finance Office of Energy & Transportation Securities and Exchange Commission Washington, D.C. 20549 Re: Motion Acquisition Corp. Amendment No. 3 to Registration Stat

As filed with the Securities and Exchange Commission on October 1, 2021

As filed with the Securities and Exchange Commission on October 1, 2021 No. 333-257681 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOTION ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-2515483 (State or other jurisdiction of incorporation or organization) (Pr

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800 Facsimile direct dial number (212) 818-8881 (212) 818-8638 email address [email protected] September 22, 2021 Division of Corporation Finance Office of Energy & Transportation Securities and Exchange Commission Washington, D.C. 20549 Re: Motion Acquisition Corp. Amendment No. 2 to Registration S

As filed with the Securities and Exchange Commission on September 22, 2021

As filed with the Securities and Exchange Commission on September 22, 2021 No. 333-257681 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOTION ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-2515483 (State or other jurisdiction of incorporation or organization)

Form of Motion Acquisition Corp. Proxy Card.

EX-99.1 8 fs42021a2ex99-1motionacq.htm FORM OF MOTION ACQUISITION CORP. PROXY CARD Exhibit 99.1 PRELIMINARY PROXY MOTION ACQUISITION CORP. c/o Graubard Miller The Chrysler Building 405 Lexington Ave New York, NY 10174 (212) 818-8800 ANNUAL MEETING YOUR VOTE IS IMPORTANT THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL Meeting TO BE HELD ON [●], 2021 The undersigned, revoking any pr

Tax Opinion of Graubard Miller

Exhibit 10.8 Adopted by the Board of Directors of Motion Acquisition Corp. on , 2021 DocGo, Inc. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this DocGo, Inc. 2021 Stock Incentive Plan (the ?Plan?) is to promote and closely align the interests of employees, officers, non-employee directors and other service providers of DocGo, Inc. (the ?Company?) and its stockholders by providing stock-bas

Form of Employment Agreement.

Exhibit 10.15 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of [DATE], by and between [EXECUTIVE] (“Executive”) and Motion Acquisition Corp., a Delaware corporation (the “Company”). WHEREAS, Executive has been serving as the [POSITION] of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (“Ambulnz”) [pursuant to that certain emplo

As filed with the Securities and Exchange Commission on September 3, 2021

As filed with the Securities and Exchange Commission on September 3, 2021 No. 333-257681 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOTION ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-2515483 (State or other jurisdiction of incorporation or organization) (

Form of Sponsor Escrow Agreement.

Exhibit 10.14 STOCK ESCROW AGREEMENT STOCK ESCROW AGREEMENT, dated as of [●], 2021 (“Agreement”), by and among Motion Acquisition Corp. (to be renamed DocGo Inc.), a Delaware corporation (“Parent”), Motion Acquisition LLC, a Delaware limited liability company (“Sponsor”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (“Escrow Agent”). WHEREAS, prior to Pa

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800 Facsimile direct dial number (212) 818-8881 (212) 818-8638 email address [email protected] September 3, 2021 Division of Corporation Finance Office of Energy & Transportation Securities and Exchange Commission Washington, D.C. 20549 Re: Motion Acquisition Corp. Amendment No. 1 to Registration St

Form of Amended and Restated Registration Rights Agreement.

Exhibit 10.13 Execution Copy AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of [●], 2021, by and among Motion Acquisition Corp., a Delaware corporation (the “Company”) and the undersigned parties listed under Investors on the signature page hereto (each, an “Investor” and collectively, the “Investors”

Joint Filing Agreement, dated as of August 25, 2021, by and between Motion Acquisition, LLC, James Travers, Michael Burdiek, Richard Vitelle, and Garo Sarkissian.

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13D (as may be amended from time to time, the ?Schedule 13D?) with respect to the Class A Common Stock of Motion Acquisition Corp.

Form of Amended and Restated Registration Rights Agreement.

Exhibit 9 Execution Copy AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into as of [?], 2021, by and among Motion Acquisition Corp.

MOTN / Motion Acquisition Corp. Class A / Motion Acquisition LLC - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

As filed with the Securities and Exchange Commission on August 16, 2021

As filed with the Securities and Exchange Commission on August 16, 2021 No. 333-257681 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOTION ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 6770 85-2515483 (State or other jurisdiction of incorporation or organization) (Pr

Consent of Steven Katz to be named as a director of New DocGo

Exhibit 99.9 Consent to be Named as a Director In connection with the filing by Motion Acquisition Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and su

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800

Graubard Miller The Chrysler Building 405 Lexington Avenue New York, N.Y. 10174-1101 (212) 818-8800 Facsimile direct dial number (212) 818-8881 (212) 818-8638 email address [email protected] August 16, 2021 Division of Corporation Finance Office of Energy & Transportation Securities and Exchange Commission Washington, D.C. 20549 Re: Motion Acquisition Corp. Registration Statement on Form S-4 F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MOTION ACQUISITION CORP. (Exact Name of Registrant as S

Motion Acquisition Corp. and DocGo Announce DocGo’s Record Preliminary Second Quarter 2021 Revenue Second quarter revenue increased 175% year-over-year DocGo raises full-year revenue outlook to at least $170 million

EX-99.1 2 ea144492ex99-1motionacq.htm PRESS RELEASE Exhibit 99.1 Motion Acquisition Corp. and DocGo Announce DocGo’s Record Preliminary Second Quarter 2021 Revenue Second quarter revenue increased 175% year-over-year DocGo raises full-year revenue outlook to at least $170 million July 20, 2021 - (New York, NY) – Motion Acquisition Corp. (“Motion”) (Nasdaq: MOTN), a special purpose acquisition comp

© 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o ANALYST DAY P R ESE N T A TIO N WHERE TELEHEALTH STOPS, WE GO Disclaimer © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 2 This presentation contemplates a business combination pursuant

Exhibit 99.2 ? 2 0 2 1 A l l R i g h t s R e s e r v e d ? D o c G o ANALYST DAY P R ESE N T A TIO N WHERE TELEHEALTH STOPS, WE GO Disclaimer ? 2 0 2 1 A l l R i g h t s R e s e r v e d ? D o c G o 2 This presentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba ?DocGo?), Motion Acquisition Corp. (?Motion?), and a wholly owned subsidiary of Mot

© 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o ANALYST DAY P R ESE N T A TIO N WHERE TELEHEALTH STOPS, WE GO Disclaimer © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 2 This presentation contemplates a business combination pursuant

Exhibit 99.2 © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o ANALYST DAY P R ESE N T A TIO N WHERE TELEHEALTH STOPS, WE GO Disclaimer © 2 0 2 1 A l l R i g h t s R e s e r v e d – D o c G o 2 This presentation contemplates a business combination pursuant to a merger agreement, by and among Ambulnz Inc. (dba “DocGo”), Motion Acquisition Corp. (“Motion”), and a wholly owned subsidiary of Mot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2021 MOTION ACQUISITION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2021 MOTION ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-39618 85-2515483 (State or Other Jurisdiction of Incorporation) (Commission File